For: | Oltean S. Modulators of alternative splicing as novel therapeutics in cancer. World J Clin Oncol 2015; 6(5): 92-95 [PMID: 26468443 DOI: 10.5306/wjco.v6.i5.92] |
---|---|
URL: | https://www.wjgnet.com/2218-4333/full/v6/i5/92.htm |
Number | Citing Articles |
1 |
Atsushi Nishida, Ayaka Oda, Atsuko Takeuchi, Tomoko Lee, Hiroyuki Awano, Naohiro Hashimoto, Yasuhiro Takeshima, Masafumi Matsuo. Staurosporine allows dystrophin expression by skipping of nonsense-encoding exon. Brain and Development 2016; 38(8): 738 doi: 10.1016/j.braindev.2016.03.003
|
2 |
Athina Mavrou, Sebastian Oltean. SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacological Research 2016; 107: 276 doi: 10.1016/j.phrs.2016.03.013
|
3 |
Feng Li, Ping Yi, Jingnan Pi, Lanfang Li, Jingyi Hui, Fang Wang, Aihua Liang, Jia Yu. QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis. Oncotarget 2016; 7(22): 32821 doi: 10.18632/oncotarget.8739
|
4 |
Barbara Rizzacasa, Elena Morini, Sabina Pucci, Michela Murdocca, Giuseppe Novelli, Francesca Amati. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies. International Journal of Molecular Sciences 2017; 18(2): 290 doi: 10.3390/ijms18020290
|
5 |
Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma. Cancer Medicine 2023; 12(4): 4895 doi: 10.1002/cam4.5174
|